ºÐÀÚÀ¯ÀüÇнÇÇè½Ç (´Ü±¹´ëÇб³ ºÐÀÚ»ý¹°Çаú)



 À̼º¿í ( 2014-08-06 09:53:04 , Hit : 1331
 Roche says to buy Danish Santaris for up to $450 million


ZURICH Mon Aug 4, 2014 6:23pm BST

08/05/2014
ZURICH (Reuters) - Roche (ROG.VX) said on Monday it will buy Santaris Pharma, a privately-held Danish biotech company that has developed a new designer molecule, for up to $450 million in cash.

Santaris, which was founded through a merger of two companies in 2003, develops drugs which work by blocking or "silencing" microRNAs -- tiny strands of RNA, or ribonucleic acid, that help turn genes into proteins.

"This new class of medicines has the potential to address difficult to treat diseases in a range of therapeutic areas," the Basel-based drugmaker said in a statement.

In the hotly pursued RNA interference field, Santaris has developed a new class of drug, known as Locked Nucleic Acid (LNA), which fine tunes the action of genes and has been shown to cut cholesterol in monkeys.

Santaris, which had previously secured funding from Roche to conduct research beyond 2014, is the second acquisition in short order for the Swiss firm, which splashed out $1.725 billion for Seragon Pharmaceuticals last month.

Since acquiring Genentech for $46.8 billion in 2009, Roche has earned a reputation as a disciplined acquirer, prepared to walk away from potential deals rather than overpay.

Chief Executive Severin Schwan abandoned a $6.8 billion deal to buy U.S gene sequencing company Illumina in 2012 and has snapped up a couple of smaller diagnostic companies this year instead of pursuing multi-billion deals.

Roche has also partnered with various companies to develop antibiotics and said in May that it would work with Inception Sciences Inc and Versant Ventures on a new company to develop therapies for patients with multiple sclerosis.

Prior to the Roche acquisition, Santaris' part-owner, Danish venture capital firm Sunstone, had been eyeing a listing in the United States.

The terms of the deal, expected to close later this month, include $250 million upfront in cash with another $200 million pending the achievement of drug development targets, Roche said.

Other Santaris partners include Bristol Myers Squibb (BMY.N) and GlaxoSmithKline Plc (GSK.L).


(Reporting By Katharina Bart; editing by David Clarke)







947   Gilead Licenses Hepatitis Therapy in India Amid Price Criticism  À̼º¿í 2014/09/17 1739
946   ÀÚ½ÅÀÇ À¯Àüü¸¦ ÇØÃ¼Çϰí ÀçÁ¶¸³ÇÏ´Â ´ÜÀÏ ¼¼Æ÷  À̼º¿í 2014/09/15 1494
945   STAP¼¼Æ÷³í¹®Ã¶È¸¿¡¼­ »õ·Ó°Ô ¹àÇôÁø »ç½Çµé  À̼º¿í 2014/09/15 1340
944   Áú ¼ÓÀÇ ¹Ì»ý¹°(vaginal microbe)ÀÌ »ý¼ºÇÏ´Â »õ·Î¿î Ç×»ýÁ¦  À̼º¿í 2014/09/15 1536
943   ÀÚ¿¬°èÀÇ Ç×»ýÁ¦ °øÀå¿¡¼­ ½ºÀ§Ä¡ ¿ªÇÒÀ» ÇÏ´Â ¼ÒºÐÀÚ ¹°Áú  À̼º¿í 2014/09/04 2002
942   Daclatasvir (Daklinza) for Chronic Hepatitis C Cleared in EU  À̼º¿í 2014/08/29 2171
941   ¼Ò¾Æ¾Ï ÃËÁø À¯ÀüÀÚ Lin28b ±Ô¸í  À̼º¿í 2014/08/18 1497
940   ¹ÙÀÌ·¯½º¸¦ ÀúÁö½ÃŰ´Â ¹æ¹ý  À̼º¿í 2014/08/15 1686
939   Sovaldi forces Incivek off the hep C market as Vertex calls it quits  À̼º¿í 2014/08/15 1548
938   Genetically 'edited' fruit could soon hit supermarket shelves  À̼º¿í 2014/08/15 1361
937   ¾Ï ¿¬±¸¸¦ À§ÇÑ »õ·Î¿î À¯ÀüÀÚ ÆíÁý ±â¼ú  À̼º¿í 2014/08/11 1491
936   New Guide RNAs for CRISPR Can Double the Targetable Genome  À̼º¿í 2014/08/09 2179
935   ÀϺ»ÀÇ ³ú°úÇÐÀÚ ¿ä½ÃŰ »ç»çÀÌÀÇ Á×À½  À̼º¿í 2014/08/08 1806
  Roche says to buy Danish Santaris for up to $450 million  À̼º¿í 2014/08/06 1331
933   ³úÁ¾¾çÀÌ ³²¼º¿¡¼­ ´õ ÈçÇÑ ÀÌÀ¯?  À̼º¿í 2014/08/06 1694
932   ¼­¾ÆÇÁ¸®Ä«ÀÇ ¿¡º¼¶ó »çÅÂ, Àü Áö±¸Àû Àç¾ÓÀ¸·Î À̾îÁú ¼ö ÀÖÀ»±î?  À̼º¿í 2014/08/06 1574
931   °¡Àå Áß¿äÇÑ °¨½ÃÀÚ p53ÀÇ »õ·Î¿î ±â´É!  À̼º¿í 2014/08/05 1449
930   HIV¸¦ Á×°ÔÇÏ´Â °­Á¦ÀûÀÎ µ¹¿¬º¯ÀÌ  À̼º¿í 2014/08/04 1490
929   ¡¸½Å¾à½ÂÀÎÀ» À§ÇÑ ÀÓ»ó½ÃÇè µ¥ÀÌÅÍ¡¹, °ø°³ÇØ¾ß Çϳª?  À̼º¿í 2014/08/01 1485
928   miRNA¸¦ ÀÌ¿ëÇÑ °èÅë¹ß»ý ºÐ¼®ÀÇ ¹®Á¦Á¡  À̼º¿í 2014/08/01 1705

[ÀÌÀü 10°³] [1]..[11][12][13][14][15][16] 17 [18][19][20]..[64] [´ÙÀ½ 10°³]
 

Copyright 1999-2023 Zeroboard / skin by ROBIN